Michael J. Brunda, PhD, director of exploratory pharmaceutical development at Roche Pharmaceuticals, died May 8, 2015, at the age of 64.
Brunda was known as one of the researchers who developed and launched Roche’s peginterferon alfa-2a (Pegasys) for the treatment of hepatitis.
Born Dec. 16, 1950, in Passaic, New Jersey, Brunda graduated from the University of Rochester in New York, and received his doctorate in microbiology/immunology from Stanford University in California. He briefly worked at the National Jewish Hospital in Denver and the National Cancer Institute in Bethesda, Maryland, before he began his career at Roche as research scientist, and then transitioned into clinical drug development.
Brunda had been a member of the AACR since 1978 and served on the Molecular Cancer Therapeutics editorial board.